HERON THERAPEUTICS, INC. /DE/ Debt Securities, Available-for-sale, Amortized Cost
HERON THERAPEUTICS, INC. /DE/ (HRTX) had Debt Securities, Available-for-sale, Amortized Cost of $21.95 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-10
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $21.95M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $18.67M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $17.98M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $12.42M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2026-06-30 | $21.95M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $18.67M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $17.98M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $12.42M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $24.12M 10-Q · filed 2025-08-08 | |
| 2025-03-31 | $31.41M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $33.47M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $45.11M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $48.97M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $51.08M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $51.72M 10-K · filed 2025-02-27 | $51.72M 10-K · filed 2024-03-12 |
| 2023-09-30 | $42.55M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $19.79M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $32.92M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $69.51M 10-K · filed 2024-03-12 | |
| 2022-09-30 | $71.36M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $34.94M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $55.01M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $67.05M 10-K · filed 2023-03-29 | |
| 2021-09-30 | $43.25M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $66.46M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $106.61M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $103.10M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $162.47M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $219.16M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $252.35M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $318.99M 10-K · filed 2021-02-24 | |
| 2019-09-30 | $196.07M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $222.82M 10-Q · filed 2019-08-05 | |
| 2019-03-31 | $265.74M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $300.62M 10-K · filed 2020-03-02 | |
| 2018-09-30 | $310.91M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $164.06M 10-Q · filed 2018-08-08 | |
| 2017-12-31 | $27.81M 10-Q · filed 2018-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Lite Strategy, Inc. (LITS) | United States | $0.049B |